NCT02064348View on ClinicalTrials.gov

A Thorough QTc Evaluation of the Effect of Semaglutide on Cardiac Repolarisation in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

168

Participants

Timeline

Start Date

February 26, 2014

Primary Completion Date

April 23, 2015

Study Completion Date

April 23, 2015

Conditions
DiabetesHealthy
Interventions
DRUG

semaglutide

Solution for subcutaneous (s.c., under the skin) injection. Dose escalation to 1.5 mg.

DRUG

placebo

Solution for s.c. injection or tablets for oral administration

DRUG

moxifloxacin

Tablets for oral administration

Trial Locations (1)

14050

Novo Nordisk Investigational Site, Berlin

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY